Staidson Beijing Biopharma Total Liabilities
Staidson Beijing Biopharma total liabilities. Based on the latest financial reports, Staidson Beijing Biopharma (300204) has total liabilities worth CN¥486.07 Million CNY (≈ $71.13 Million USD) as of March 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Check Staidson Beijing Biopharma (300204) liquid assets ratio to evaluate the company's liquid asset resilience ratio.
Total Liabilities of Staidson Beijing Biopharma (2007–2025)
Total liabilities of Staidson Beijing Biopharma from 2007 to 2025. This chart illustrates how Staidson Beijing Biopharma's total liabilities have evolved over time, based on quarterly financial data. Explore 300204 long-term asset investment ratio to see how much of total assets are deployed in long-term investments.
Staidson Beijing Biopharma Competitors by Total Liabilities
The table below lists competitors of Staidson Beijing Biopharma ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
MeHow Innovative Ltd. A
SHE:301363
|
China | CN¥467.62 Million |
|
Shenzhen Qingyi Photomask Ltd
SHG:688138
|
China | CN¥1.12 Billion |
|
Opera Ltd
NASDAQ:OPRA
|
USA | $148.76 Million |
|
Anhui Guangxin Agrochemical Co Ltd
SHG:603599
|
China | CN¥4.16 Billion |
|
Beijing Bei Mo Gao Ke Friction Mate
SHE:002985
|
China | CN¥918.30 Million |
|
Banvida
SN:BANVIDA
|
Chile | CL$115.77 Billion |
|
One Software Technologies Ltd
TA:ONE
|
Israel | ILA1.82 Billion |
|
Sobha Limited
NSE:SOBHA
|
India | Rs-47.20 Billion |
Liability Composition Analysis (2007–2025)
This chart breaks down Staidson Beijing Biopharma's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see how large is Staidson Beijing Biopharma's balance sheet.
Liquidity & Leverage Metrics
Staidson Beijing Biopharma Total Liabilities Ratios Explained
Staidson Beijing Biopharma total liabilities ratios compare its liabilities with its current assets, cash and shareholder equity.
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 2.00 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.60 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.38 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Staidson Beijing Biopharma's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Staidson Beijing Biopharma (2007–2025)
The table below shows the annual total liabilities of Staidson Beijing Biopharma from 2007 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | CN¥459.48 Million ≈ $67.24 Million |
+97.33% |
| 2024-12-31 | CN¥232.85 Million ≈ $34.07 Million |
-25.26% |
| 2023-12-31 | CN¥311.55 Million ≈ $45.59 Million |
-1.24% |
| 2022-12-31 | CN¥315.45 Million ≈ $46.16 Million |
+14.19% |
| 2021-12-31 | CN¥276.25 Million ≈ $40.42 Million |
+2.81% |
| 2020-12-31 | CN¥268.70 Million ≈ $39.32 Million |
+18.27% |
| 2019-12-31 | CN¥227.18 Million ≈ $33.24 Million |
-27.72% |
| 2018-12-31 | CN¥314.30 Million ≈ $45.99 Million |
-25.01% |
| 2017-12-31 | CN¥419.14 Million ≈ $61.33 Million |
-3.05% |
| 2016-12-31 | CN¥432.32 Million ≈ $63.26 Million |
+11.69% |
| 2015-12-31 | CN¥387.06 Million ≈ $56.64 Million |
+30.09% |
| 2014-12-31 | CN¥297.54 Million ≈ $43.54 Million |
+16.47% |
| 2013-12-31 | CN¥255.47 Million ≈ $37.38 Million |
+32.96% |
| 2012-12-31 | CN¥192.15 Million ≈ $28.12 Million |
+306.05% |
| 2011-12-31 | CN¥47.32 Million ≈ $6.92 Million |
-52.03% |
| 2010-12-31 | CN¥98.66 Million ≈ $14.44 Million |
+239.79% |
| 2009-12-31 | CN¥29.03 Million ≈ $4.25 Million |
-0.73% |
| 2008-12-31 | CN¥29.25 Million ≈ $4.28 Million |
-39.50% |
| 2007-12-31 | CN¥48.35 Million ≈ $7.07 Million |
-- |
About Staidson Beijing Biopharma
Staidson (Beijing) BioPharmaceuticals Co., Ltd. primarily engages in the research, development, production, and marketing of therapeutic and biological drugs in China. The company offers protein drugs, including therapeutic monoclonal antibody drugs; chemical drugs; and drugs for urinary, intestinal, infectious, autoimmune, nervous system, and other diseases. It also provides treatments for respi… Read more